Xortx Therapeutics (TSE:XRTX) has released an update.
XORTX Therapeutics has published a study outlining the impact of increased serum uric acid on the progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD), revealing that it exacerbates the disease. The research indicates that XORTX’s drug XORLO™, by inhibiting xanthine oxidase, can mitigate these effects and potentially slow the progression of ADPKD. This insight is critical for future clinical studies and offers hope for better management of a condition affecting over 10 million people globally.
For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.
